Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Company Overview - Verona Pharma plc is a biopharmaceutical company focused on developing and commercializing innovative therapies for chronic respiratory diseases with significant unmet medical needs [5] - The company's first commercial product, OhtuvayreTM (ensifentrine), is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule [5] - Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory diseases [5] Upcoming Financial Results - Verona Pharma will report its financial results for the second quarter ended June 30, 2024, on August 8, 2024 [1] - An investment community conference call will be hosted at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update [1] Communication and Participation - A live webcast of the conference call will be available on the company's website, and an audio replay will be accessible for 90 days [2] - For participation, callers can dial specific numbers provided for both U.S. and international callers [4]